QazCovid-in, commercially known as QazVac, is a

COVID-19 vaccine A COVID19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 ( COVID19). Prior to the COVID19 pandemic, an e ...

developed by the Research Institute for Biological Safety Problems in

Kazakhstan Kazakhstan, officially the Republic of Kazakhstan, is a transcontinental country located mainly in Central Asia and partly in Eastern Europe. It borders Russia to the north and west, China to the east, Kyrgyzstan to the southeast, Uzbeki ...

. QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.

Manufacturing

The vaccine can be stored at standard refrigeration temperatures (2°C-8°C) and is a two-dose régime with the doses administered twenty-one days apart.The vaccine was first manufactured by Kazakhstan's Research Institute of Biological Safety Problems. Production capacity has been capped at 50,000 doses per month. Beginning in June 2021, the vaccine is slated to be packaged in large bulk to be bottled in

Turkey Turkey ( tr, Türkiye ), officially the Republic of Türkiye ( tr, Türkiye Cumhuriyeti, links=no ), is a list of transcontinental countries, transcontinental country located mainly on the Anatolia, Anatolian Peninsula in Western Asia, with ...

by a major Turkish company. This will allow for a production capacity of 500,000-600,000 doses per month. The contract is still being negotiated, despite earlier claims suggesting that the deal had already been finalized. In October 2021, it was announced that the vaccine would be supplied to Afghanistan and other countries in 2022.

History

Clinical trials

In September 2020, QazVac started in Phase I/II clinical trials. In December 2020, QazVac is currently in Phase III clinical trials, which is expected to be fully completed by 9 July 2021. It is unclear when the first preliminary results will be published. The administration of the vaccine for the general population began at the end of April 2021. The Research Institute Kunsulu Zakarya's Director General's justification is that the trial is almost 50% completed and "people who have received hevaccine feel well; there have been no side-effects and the effectiveness of the vaccine is high". In September 2021, a study was published to eClinicalMedicine, published by The Lancet. The study’s findings were that the “QazCovid-in® vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials.”

Authorization

Economics

The first batch of 50,000 doses was delivered on 26 April 2021, and vaccination began shortly after. In June 2021, the capacity will increase to 100,000 doses per month, regardless of the contract for bottling in Turkey.

References

External links

{{Portal bar , Medicine , Viruses , COVID-19 Clinical trials Kazakh COVID-19 vaccines Inactivated vaccines Science and technology in Kazakhstan